FRESENIUS MEDICAL CA

FME
Delayed Quote. Delayed  - 12/04 11:38:57 am
68.32EUR -0.52%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 18 86121 231
EBITDA1 4 1694 607
Operating profit (EBIT)1 2 4502 858
Operating Margin 13,0%13,5%
Pre-Tax Profit (EBT)1 1 9872 464
Net income1 1 2951 532
Net margin 6,87%7,22%
EPS2 4,275,18
Dividend per Share2 1,301,40
Last update 02/20/202011/23/2020
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 13 78715 175
Net Cash position1 --
Leverage (Debt / EBITDA) 3,31x3,29x
Free Cash Flow1 1 5561 953
ROE (Net Profit / Equities) 11,5%10,5%
Shareholders' equity1 11 21814 549
ROA (Net Profit / Asset) 4,06%4,07%
Assets1 31 93337 670
Book Value Per Share2 42,650,5
Cash Flow per Share2 9,1510,7
Capex1 1 2141 253
Capex / Sales 6,44%5,90%
Last update 02/20/202011/23/2020
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 24 251 M $ -
Entreprise Value (EV) 39 426 M $ 37 956 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) 16,0x 14,8x
Capitalization / Revenue 1,14x 1,09x
EV / Revenue 1,86x 1,78x
EV / EBITDA 8,56x 8,28x
Yield (DPS / Price) 1,68% 1,78%
Price to book (Price / BVPS) 1,64x 1,52x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 13,5% 13,7%
Operating Leverage (Delta EBIT / Delta Sales) 1,33x 1,42x
Net Margin (Net Profit / Revenue) 7,22% 7,47%
ROA (Net Profit / Asset) 4,07% 4,71%
ROE (Net Profit / Equities) 10,5% 10,9%
Rate of Dividend 26,9% 26,4%
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   5,90% 5,90%
Cash Flow / Sales 14,8% 14,0%
Capital Intensity (Assets / Sales) 1,77x 1,59x
Financial Leverage (Net Debt / EBITDA) 3,29x 2,88x
Price Earning Ratio
EPS & Dividend